Sector News

Drugmakers omit detail on FDA drug rejections, study finds

June 15, 2015
Life sciences
Pharmaceutical companies are holding back information from the public on why their medicines have been rejected by the US Food and Drug Administration, a study published in the BMJ has found.
 
An analysis of 61 FDA complete response letters sent out between August 2008 and June 2013 has revealed that the information released by drugmakers on the reasons for refusal only fully matched the regulator’s actual issues in 14% of cases. 
 
The researchers also found that in 21% there was no concordance between the CRL and the company’s press release at all, while nearly a fifth (18%) of CRLs weren’t even reported on. And only 59% of pharmas reported the need for extra clinical trials if they had been requested by the CRL, while of seven CRLs reporting higher mortality rates in treated participants only one associated press release reported this fact.
 
The researchers conclude that there are substantial differences in content between confidential CRLs and the information issued by sponsors, and so press releases “are generally an incomplete source of reasons for FDA non-approval of applications”.
 
CRLs are currently confidential, but campaigners have long argued that the US regulator should fully disclose this information, as occurs across the pond in Europe. The potential benefits of this would include “better informing the development of new drugs, facilitating a richer public health discourse, and counteracting misconceptions regarding FDA’s reasons for denial of applications,” the researchers argue.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.